Revolutionising Wound Care Solutions
CleverSkin Technologies Limited is a London-based medical technology firm dedicated to transforming wound care with our innovative product, medical foam and wound dressing - CleverSkin®. Our advanced medical wound dressing is designed to promote faster healing and improved patient outcomes for a variety of wounds. Join us in pioneering the future of wound care.
Wound Dressing Features
Advanced Medical Foam
The newly developed medical foam serves as an advanced wound dressing, providing a moist environment conducive to healing. Its unique composition allows for high absorbency, effectively managing exudate and reducing the risk of maceration. By maintaining optimal moisture levels, the foam supports the natural healing process and minimises patient discomfort.
Faster Healing and Improved Outcomes
Clinical evaluations have demonstrated that this medical foam significantly accelerates the healing process. Patients treated with the foam experienced reduced healing times and fewer complications compared to traditional dressings. The foam's antimicrobial properties also help prevent infection, further contributing to improved patient outcomes.
Versatility in Wound Management
Designed for versatility, the medical foam is suitable for a wide range of wounds, including pressure ulcers, diabetic foot ulcers, surgical wounds, and traumatic injuries. Its conformable nature ensures it adapts to various wound shapes and sizes, providing effective coverage and protection. The foam can be easily applied and removed, enhancing patient comfort during dressing changes.
We are inviting interested parties
to discover the future of wound care and
discuss investment and manufacturing opportunities. Should you interested, use the contact form below and send us your message. Thank you in advance in your interest in CleverSkin® - innovative medical foam - new generation of wound dressing.
CleverSkin Team
Dr John Butler
Medical Director
Mind-body medicine and mental health medical professional.
Dr John Butler is a highly regarded therapist with over 40 years of proven experience as a successful clinical practitioner.
PhD (Med Sci., Lond.), MBSH, MBPsS, MA, BA(Hons.), BSc(Hons.), DHP, Dip A.T., CHT, FNRHP. Registered with U.K.C.P., E.A.P., B.P.S., B.S.H., B.A.S., A.C.H.E.
Vadzim Tsitou
Chief Executive Officer
Vadzim Tsitou, MBA is a seasoned product development scientist with a strong background in materials science and medical device engineering background. He is passionate about translating scientific research into practical applications and plays a crucial role in designing and testing innovative solutions. As the CEO of CleverSkin Technologies Limited based in London, UK, he focuses on commercialising proprietary and advanced wound dressings (the blessings under the CleverSkin® brand).
CleverSkin Technologies Limited Unveils Ground-Breaking Advanced Wound Dressing
Medica 2025, Düsseldorf, Germany – November 2025.
CleverSkin Technologies Limited successfully launched its new CleverSkin® Advanced Wound Dressing at Medica 2025, Germany, marking a significant milestone in modern wound-care innovation. The product attracted strong interest from clinicians, distributors, and healthcare decision-makers due to its performance, ease of use, and cost-saving potential.
The new dressing uses a next-generation polyurethane matrix, combined with engineered micro-porosity and advanced structural layering, to support faster healing, maintain an optimal moisture environment, and improve patient comfort. Its design reduces dressing change frequency and reduces overall resource use for hospitals, clinics, and community care teams.
A Clinical and Technical Step Forward
Dr John Butler, Medical Director at CleverSkin Technologies Limited, commented on the clinical significance of the launch:
“CleverSkin combines superior vapour transmission, antimicrobial resistance and structural stability designed to support rapid and predictable wound progression. The dressing adheres intelligently to the skin surrounding the wound, is easily removed without trauma and maintains healthy tissue while protecting compromised skin. Our laboratory and real-world evaluations show a measurable reduction in exudate-related complications, including in chronic and difficult wounds, with a meaningful improvement in patient comfort. This solution offers clinicians a reliable, high-performance option that aligns with current evidence-based wound-care standards.”
Impact for the NHS and Healthcare Providers
Mr Vadzim Tsitou, CEO and Founder at CleverSkin Technologies Limited, also highlighted the benefits for UK and international healthcare systems.
Strong International Feedback
The product also received excellent feedback from international partners, including Danialex, a leading Brazilian healthcare distributor.
Mr Alexandre Vandelli, Director at Danialex, Brazil, shared his impression after reviewing the product at Medica:
“CleverSkin® polyurethane advanced wound dressing stands out because of its structure, strength and consistency. The material feels exceptionally stable and maintains integrity even under demanding conditions. This is essential in Brazil, where climate and patient mobility can affect dressing performance. The combination of durability, breathability and ease of application makes it one of the most promising wound-care products we have seen in recent years.”
Funding Round Now Open
Following its successful debut at Medica 2025, CleverSkin Technologies Limited has officially opened a new fundraising round. The company is now inviting private and institutional investors to participate in its Series A round to support global expansion, clinical studies, and increased manufacturing capacity.
Investors interested in participating may request a meeting, financial overview, or investment deck by contacting us via https://cleverskintechnologies.co.uk.